Group items matching

in title, tags, annotations or url

Planetary Resources is establishing a new paradigm for resource discovery and utilization that will bring the solar system into humanity's sphere of influence. Our technical principals boast extensive experience in all phases of robotic space missions, from designing and building, to testing and operating.

Academia.edu is a place to share and follow research

"Metacognitive experiences and the intricacies of setting people straight" decision making by few arguments better than more cognitive greed, info overload http://ed.iiqii.de/gallery/Science-TheOnlyNews/FrontalCortex_wired_com warum wir nur bis 3 zählen können

The International Space Apps Challenge is your opportunity to build, create, and invent new solutions to challenges of global importance.

SETILive is taking the Search for Extraterrestrial Intelligence (SETI) directly to you by presenting radio frequency signals LIVE from the SETI Institute's Allen Telescope Array (ATA) while it's pointed at stars that, based on Kepler exoplanet discoveries, have the best chances of being home to an alien civilization. We'll also be putting you "in the loop" where if enough of you see a potential extraterrestrial (ET) signal in the same data, then within minutes, the ATA will be interrupted and sent back to take a second look. The data you see will be from frequencies where human-made Radio Frequency Interference (RFI) crowds them and we believe the human eye will have a better chance than SETI's computer algorithms to find ET signals there.

AIAI is a technology transfer organisation that promotes the application of Artificial Intelligence research for the benefit of commercial, industrial, and government clients. AIAI has considerable experience of working with small innovative companies, and with research groups in larger corporations.

http://www.ox.ac.uk/media/news_stories/2010/101207.html Peter Rothwell: In this new work, scientists from Oxford, Edinburgh, London and Japan used data on over 670 deaths from cancer in a range of randomised trials involving over 25,000 people. These trials compared daily use of aspirin against no aspirin and were done originally to look for any preventative effect against heart disease. The results, published in the Lancet, showed that aspirin reduced death due to any cancer by around 20% during the trials. But the benefits of aspirin only became apparent after taking the drug for 5 years or more, suggesting aspirin works by slowing or preventing the early stages of the disease so that the effect is only seen much later. After 5 years of taking aspirin, the data from patients in the trials showed that death rates were 34% less for all cancers and as much as 54% less for gastrointestinal cancers, such as oesophagus, stomach, bowel, pancreas and liver cancers.

Online courses from the world's top scholars

The Future of Online Education for anyone, anywhere, anytime